Center Laboratories Inc (CenterLab: 4123.TWO), a Taiwan-based-pharmaceutical company, has met its primary endpoint in a phase two clinical trial of anti-diabetic drug, CS02, it was reported on Friday.
The top-line results of the product's phase two clinical trial revealed a significant decrease of glycated haemoglobin in treated patients compared to the placebo group by 0.45% (p value = 0.0098).
The product is an orally administered small molecule drug under development following the abbreviated 505(b)(2) regulatory pathway for new drug approval. For further development of CS02, CenterLab is actively seeking global partners for co-development or licensing opportunities.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults